Transgene Announces Upcoming Investor Meetings
12 Aprile 2021 - 5:45PM
Business Wire
Regulatory News:
Strasbourg, France, April 12, 2021, 05:45 pm CET – Transgene
(Paris:TNG), a biotech company that designs and develops
virus-based immunotherapeutics against cancer, today announces that
Management will participate in the upcoming investor events set out
below:
- SmallCap Event – Digital event 14
& 15 April 2021
- KEMPEN LIFE SCIENCES CONFERENCE -
2021 Thematic Virtual Series 21 April 2021 - Immuno and Targeted
Oncology
- Spring European Midcap Event –
Digital event 22 & 23 June 2021
***
About Transgene
Transgene (Euronext: TNG) is a biotechnology company focused on
designing and developing targeted immunotherapies for the treatment
of cancer. Transgene’s programs utilize viral vector technology
with the goal of indirectly or directly killing cancer cells. The
Company’s clinical-stage programs consist of two therapeutic
vaccines (TG4001 for the treatment of HPV-positive cancers, and
TG4050, the first individualized therapeutic vaccine based on the
myvac® platform) as well as two oncolytic viruses (TG6002 for the
treatment of solid tumors, and BT-001, the first oncolytic virus
based on the Invir.IO™ platform). With Transgene’s myvac® platform,
therapeutic vaccination enters the field of precision medicine with
a novel immunotherapy that is fully tailored to each individual.
The myvac® approach allows the generation of a virus-based
immunotherapy that encodes patient-specific mutations identified
and selected by Artificial Intelligence capabilities provided by
its partner NEC. With its proprietary platform Invir.IO™, Transgene
is building on its viral vector engineering expertise to design a
new generation of multifunctional oncolytic viruses. Transgene has
an ongoing Invir.IO™ collaboration with AstraZeneca. Additional
information about Transgene is available at: Follow us on Twitter:
@TransgeneSA
Disclaimer
This press release contains forward-looking statements, which
are subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those anticipated. The
occurrence of any of these risks could have a significant negative
outcome for the Company’s activities, perspectives, financial
situation, results, regulatory authorities’ agreement with
development phases, and development. The Company’s ability to
commercialize its products depends on but is not limited to the
following factors: positive pre-clinical data may not be predictive
of human clinical results, the success of clinical studies, the
ability to obtain financing and/or partnerships for product
manufacturing, development and commercialization, and marketing
approval by government regulatory authorities. For a discussion of
risks and uncertainties which could cause the Company’s actual
results, financial condition, performance or achievements to differ
from those contained in the forward-looking statements, please
refer to the Risk Factors (“Facteurs de Risque”) section of the
Universal Registration Document, available on the AMF website
(http://www.amf-france.org) or on Transgene’s website
(www.transgene.fr). Forward-looking statements speak only as of the
date on which they are made and Transgene undertakes no obligation
to update these forward-looking statements, even if new information
becomes available in the future.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210412005658/en/
Transgene: Lucie Larguier Director Corporate
Communications & IR +33 (0)3 88 27 91 04
investorrelations@transgene.fr
Media: Citigate Dewe Rogerson David Dible/Sylvie
Berrebi + 44 (0)20 7638 9571
transgene@citigatedewerogerson.com
Grafico Azioni Transgene (EU:TNG)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Transgene (EU:TNG)
Storico
Da Apr 2023 a Apr 2024